Caribou Biosciences Q3 2026 Earnings Date & Estimates

Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA. Its therapies are intended to enhance the persistence, activity and availability of engineered immune cells by making targeted genetic changes during cell development. These candidates remain investigational and have not been approved for general commercial use.

Founded in 2011 and headquartered in Berkeley, California, Caribou was built around CRISPR technology co-developed by a group that included Nobel Prize-winning scientist Jennifer Doudna. Rachel Haurwitz, Ph.D., a co-founder of the company, has served as its president and chief executive officer. Caribou conducts its biotechnology development primarily in the United States and works with research, clinical and industry partners to advance its cell-therapy programs.